Lyon, France – July 23, 2008 – Flamel Technologies (Nasdaq: FLML) expects to release its
second quarter 2008 financial results on Wednesday, August 6th after the market close. A
conference call to discuss the second quarter financial results has been scheduled for
Thursday, August 7th at 8:30 AM (EDT). A question and answer period is expected to follow
the discussion of results.

To participate in the conference call, investors in the US and Canada are invited to dial
1-800-374-1498. International callers are invited to call (1) 706-634-7261. The Conference
ID number is: 57373983.

Flamel Technologies, S.A. is a biopharmaceutical company principally engaged in the
development of two unique polymer-based delivery technologies for medical applications.
Flamel's Medusa® technology is designed to deliver controlled-release formulations of
therapeutic proteins and peptides, without reduction in bioactivity. Micropump® is a
controlled release and taste-masking technology for the oral administration of small molecule
drugs; it is the intellectual platform licensed by GlaxoSmithKline for the development of
COREG CR™.

Charles Marlio, Director of Strategic Planning and Investor Relations
Tel: (33) 4-7278-3434
Fax: (33) 4-7278-3435
Marlio@flamel.com

This document contains a number of matters, particularly as related to financial projections
and the status of various research projects and technology platforms, that constitute forward-
looking statements within the meaning of the Private Securities Litigation Reform Act of
1995.
The presentation reflects the current view of management with respect to future events and is
subject to risks and uncertainties that could cause actual results to differ materially from
those contemplated in such forward-looking statements.
These risks include risks that products in the development stage may not achieve scientific
objectives or milestones or meet stringent regulatory requirements, uncertainties regarding
market acceptance of products in development, the impact of competitive products and
pricing, and the risks associated with Flamel's reliance on outside parties and key strategic
alliances.
These and other risks are described more fully in Flamel's Annual Report on the Securities
and Exchange Commission Form 20-F for the year ended December 31, 2007.

This document contains a number of matters, particularly as related to financial projections and the status of various research projects and technology platforms, that constitute forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel's reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel's Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2007